Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A novel alpha-particle radiation therapy, [212Pb]VMT-a-NET, is showing promising results for patients with advanced neuroendocrine tumors (NETs). Interim data from a phase 1/2a trial presented at the 2026 NANETS Symposium revealed an 18-month progression-free survival rate of 71.5% with no grade 4 or 5 treatment-related adverse events. The findings suggest durable responses with a manageable safety profile.
A targeted alpha-particle therapy called [212Pb]VMT-a-NET is turning heads in the neuroendocrine tumor (NET) space. Interim data from a phase 1/2a clinical trial, presented at the 2026 NANETS Multidisciplinary NET Medical Symposium, showed meaningful tumor responses and a favorable safety profile in patients with advanced, well-differentiated SSTR2-expressing NETs who had progressed on prior systemic therapy.
The trial enrolled 68 patients across three dose cohorts. In patients whose tumors were fully SSTR2-positive, disease control rates exceeded 90% in cohort 2 and hit 100% in cohort 3. Objective response rates reached 36.8% and 47.1% in cohorts 2 and 3, respectively, and 82% of patients completed all four planned doses.
By the Numbers:
Why it matters: NETs are notoriously difficult to treat once they progress on standard therapies. [212Pb]VMT-a-NET's strong disease control rates and clean safety profile — with no renal or swallowing toxicity signals — could position it as a meaningful new option in the radionuclide therapy landscape.
